section name header

Pronunciation

hye-drox-ee-yoor-EE-a

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification: antimetabolites

Indications

High Alert

Droxia, Siklos, and Xromi:

Hydrea:

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Well absorbed following oral administration.

Distribution: Crosses the blood-brain barrier; concentrates in RBCs and leukocytes.

Metabolism/Excretion: 50% excreted unchanged by the kidneys; 50% metabolized by the liver and eliminated as respiratory CO.

Half-life: 3–4 hr.

Time/Action Profile

(effects on blood counts)

ROUTEONSETPEAKDURATION
PO7 days10 days21 days

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: alopecia, cutaneous vasculitis, exacerbation of postradiation erythema, erythema, pruritus, rash.

GU: fertility (males).

Hemat: leukopenia, anemia, hemolytic anemia, macrocytosis, thrombocytopenia.

Metab: hyperuricemia.

Resp: INTERSTITIAL LUNG DISEASE.
Misc: chills, fever, malaise, (INCLUDING LEUKEMIA AND SKIN CANCER)SECONDARY MALIGNANCY .

Interactions

Drug-Drug:

Route/Dosage

see Calculator

Head and Neck Cancer or Resistant Chronic Myelogenous Leukemia

Renal Impairment

Sickle Cell Anemia

Renal Impairment

Renal Impairment

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations: Toxicity and Overdose:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Droxia, Hydrea, Siklos, Xromi